Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Hyperhidrosis Equipment Supplied In Usa
4 equipment items found
Manufactured by:miraDry, Inc. based inNewport Beach, CALIFORNIA (USA)
For millions of people globally, excessive sweating or hyperhidrosis is a condition that can interfere with daily life. Excessive underarm sweat, or primary axillary hyperhidrosis, often goes untreated despite being the most bothersome and common form of excessive sweating. Hyperhidrosis is an uncontrollable issue where sweat glands are ...
Manufactured by:Span America Medical Systems, Inc. based inGreenville, SOUTH CAROLINA (USA)
The system delivers time-tested, effective removal of excess moisture and heat within the microclimate from profuse sweating (hyperhidrosis) caused or exacerbated by thick layers of subcutaneous adipose tissue, obesity-related immobility and the inability to reposition effectively and ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-1300 (recombinant T172R/G173Q double-mutant cocaine esterase 200 mg, IV solution) is being developed under an Investigational New Drug application (IND) for the treatment of cocaine intoxication. It has been designated a Breakthrough Therapy by the FDA. Currently there is no specific pharmacotherapy indicated for cocaine intoxication, a state characterized by acute agitation, hyperthermia, ...
Manufactured by:RedHill Biopharma Ltd. based inTel-Aviv, ISRAEL
MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage ...